Skip to the page

Data / Drug companies / Par Health USA, LLC

Par Health USA, LLC: 100 products in the FDA NDC directory, labeler code 49884

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Par Health USA, LLC (labeler code 49884) lists 100 products in the FDA National Drug Code Directory, covering 38 finished drugs by generic name. By type: 100 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 17, 2025.

The request: Watch Par Health USA, LLC (FDA labeler code 49884): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
49884
Products in commercial distribution
100
Packages
124
Finished drugs by generic name
38
Prescription products
100
Over the counter products
0
Controlled substance products
Schedule II 8, Schedule IV 11
Flagged as original packager
92 of 92 products that carry the flag
Started marketing in the last 12 months
0
Products with a marketing end date set
2
Earliest marketing start
December 13, 1979
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)9696%
Authorized generics (NDA)33%
New drug applications (NDA)11%

Products by type

TypeProductsShare
Prescription drugs100100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet2424%
Tablet, orally disintegrating1919%
Tablet, film coated1414%
Capsule1313%
Capsule, extended release88%
Powder, for suspension44%
Kit44%
Powder, for solution44%
Tablet, coated22%
Capsule, delayed release22%
Tablet, delayed release11%
Powder11%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Glycerol Phenylbutyrate49884-264LiquidGeneric drugs (ANDA)October 17, 2025
Ibuprofen and famotidine49884-366TabletGeneric drugs (ANDA)March 22, 2024
Dexlansoprazole49884-147Capsule, delayed releaseGeneric drugs (ANDA)June 10, 2023
Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride49884-151CapsuleGeneric drugs (ANDA)March 7, 2023
Diclofenac Potassium49884-905Powder, for solutionGeneric drugs (ANDA)January 3, 2023
Dexlansoprazole49884-148Capsule, delayed releaseGeneric drugs (ANDA)November 22, 2022
Colchicine49884-171Tablet, film coatedGeneric drugs (ANDA)September 27, 2022
Everolimus49884-159TabletGeneric drugs (ANDA)March 31, 2022
Tolvaptan49884-770TabletGeneric drugs (ANDA)March 10, 2022
Tolvaptan49884-768TabletGeneric drugs (ANDA)March 10, 2022
Everolimus49884-283TabletGeneric drugs (ANDA)January 26, 2022
Glycopyrrolate49884-042SolutionGeneric drugs (ANDA)January 4, 2022
Isosorbide Dinitrate49884-556TabletGeneric drugs (ANDA)December 21, 2021
Varenicline49884-944KitGeneric drugs (ANDA)September 21, 2021
Varenicline49884-156Tablet, film coatedGeneric drugs (ANDA)September 21, 2021
Varenicline49884-155Tablet, film coatedGeneric drugs (ANDA)September 21, 2021
Sapropterin dihydrochloride49884-948Powder, for solutionGeneric drugs (ANDA)October 1, 2020
Sapropterin dihydrochloride49884-873Powder, for solutionGeneric drugs (ANDA)October 1, 2020
Sapropterin dihydrochloride49884-720TabletGeneric drugs (ANDA)October 1, 2020
Penicillamine49884-146CapsuleGeneric drugs (ANDA)January 8, 2020
Doxylamine Succinate and Pyridoxine Hydrochloride49884-186Tablet, delayed releaseGeneric drugs (ANDA)December 19, 2019
Trientine Hydrochloride49884-060CapsuleGeneric drugs (ANDA)September 27, 2019
Aliskiren49884-425Tablet, film coatedGeneric drugs (ANDA)March 25, 2019
Aliskiren49884-424Tablet, film coatedGeneric drugs (ANDA)March 25, 2019
Midodrine Hydrochloride49884-874TabletGeneric drugs (ANDA)October 29, 2018

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.